At this year’s annual EuroPCR meeting, Boston Scientific (NYSE:BSXtouted results from the first trial to compare two drug-coated balloons with different drug formulations – Boston Scientific’s Agent paclitaxel-coated PTCA device and B. Braun’s SeQuent Please balloon. The 125-patient study evaluated the balloons in patients with in-stent restenosis of a lesion previously treated with a drug-eluting stent or drug-coated balloon. […]
Amaranth Medical
Here’s how Amaranth Medical plans to get ahead with its bioresorbable scaffold tech
There are two ways to make a bioresorbable, drug-eluting scaffold, according to Amaranth Medical CEO Kamal Ramzipoor. “The Amaranth way, or the conventional way, which our competition is using,” he told Drug Delivery Business News. “What we’ve seen throughout the years is the conventional method has some very significant limitations. And that’s what has manifested itself into, unfortunately, what’s going […]
Amaranth Medical looks to recapture the potential of bioresorbable scaffolds
Dr. Antonio Colombo had finished his presentation of 9-month data for Amaranth Medical‘s Aptitude sirolimus-eluting bioresorbable scaffold when an audience member asked about adverse events. He told the EuroPCR attendee that they hadn’t seen any adverse events related to the device during the trial – and that’s unusual. Bioresorbable scaffolds, like Abbott‘s (NYSE:ABT) Absorb, have been […]
EuroPCR Roundup: Medtronic’s Resolute Onyx meets primary endpoint in small-vessel trial
Medtronic‘s (NYSE:MDT) Resolute Onyx 2.0mm drug-eluting stent met its primary endpoint of target lesion failure at 1 year for the treatment of coronary artery disease in extra-small vessels, according to data from the Resolute Onyx 2.0mm trial. The trial enrolled 101 patients with extra-small vessel sizes ranging from 2 millimeters to 2.25 millimeters. Patients treated with […]
California startup lands $20M to support bioresorbable scaffold
Mountain View, Calif.-based Amaranth Medical announced a $20 million Series B funding round in support of development of the company’s flagship Fortitude bioresorbable scaffold, a device-based treatment for coronary artery disease.
Amaranth plans to use the funds to further progress in clinical trials in hopes of winning CE Mark approval in the European Union, according to a company statement.
